IgE-selective immunoadsorption for severe atopic dermatitis

Michael Kasperkiewicz*, Sophie Charlotte Mook, Diana Knuth-Rehr, Artem Vorobyev, Ralf J. Ludwig, Detlef Zillikens, Philip Muck, Enno Schmidt

*Corresponding author for this work
1 Citation (Scopus)


Introduction: Recent reports proposed the application of immunoadsorption (IA) for patients with recalcitrant atopic dermatitis (AD) and high-serum IgE levels. However, experience with this novel treatment approach, especially with the newly available IgE-specific adsorber, is limited and recommendation for its use in clinical practice awaits evidence from more studies. Materials and methods: Patients with severe AD (SCORAD ≥= 60) and total serum IgE levels ≥750 kU/L were included in this study. The treatment protocol consisted of two cycles of five consecutive treatments with IgE-selective IA 3 weeks apart. Results: Ten patients were enrolled and four patients completed the study. The mean SCORAD was significantly improved by up to 43% within a few weeks and until the end of a 6-month follow-up period, with 50% of patients achieving an at least 50% individual reduction of the baseline SCORAD. Each IA cycle induced a temporal average decrement of total serum levels of IgE, IgM, IgA, and IgG by 92, 43, 38, and 35%, respectively. Except for one case of Staphylococcus aureus septicemia, no major adverse events occurred. Conclusion: Although limited by a considerable withdrawal rate, our observations strengthen our and other recent results further suggesting that IgE-selective IA is an effective treatment option for patients severely affected by AD with highly elevated IgE levels.

Original languageEnglish
Article number27
JournalFrontiers in medicine
Issue numberFEB
Number of pages6
Publication statusPublished - 01.02.2018


Dive into the research topics of 'IgE-selective immunoadsorption for severe atopic dermatitis'. Together they form a unique fingerprint.

Cite this